Literature DB >> 15362567

Haplotype architecture of the norepinephrine transporter gene SLC6A2 in four populations.

Inna Belfer1, Gabriel Phillips, Julie Taubman, Heather Hipp, Robert H Lipsky, Mary-Anne Enoch, Mitchell B Max, David Goldman.   

Abstract

The norepinephrine transporter (NET) regulates levels of monoamine neurotransmitters integral to a variety of behaviors and autonomic functions. Two SLC6A2 polymorphisms have been used in genetic association studies, generating intriguing but nondefinitive results on traits such as hypertension and mood. One of these SLC6A2 variants is functional but rare. The other is common but not informative over the entire 48 kb SLC6A2 region and is insufficient to capture the functional diversity potentially contained within any SLC6A2 region. To elucidate SLC6A2 haplotype structure and define markers sufficient to capture haplotype diversity within detected haplotype blocks, 26 single-nucleotide polymorphisms (SNPs) were genotyped in 384 individuals evenly divided across Finnish Caucasian, US Caucasian, Plains American Indian, and African American populations. Three conserved blocks, 13.6, 12.5, and 25 kb in size and showing little evidence for historical recombination were observed in all populations. Haplotype diversity in block 1 and numbers of common haplotypes were highest in African Americans, among whom 5-6 optimal markers were sufficient to maximize diversity of each block. For other populations, 2-3 markers/block sufficed, but the optimal markers differed across populations. The SLC6A2 haplotype map and 25-marker panel (excluding the monomorphic one) is a comprehensive tool for genetic linkage studies on phenotypes related to NET function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362567     DOI: 10.1007/s10038-004-0140-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  32 in total

1.  The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Authors:  Luc Jasmin; Duc Tien; David Weinshenker; Richard D Palmiter; Paul G Green; Gabriella Janni; Peter T Ohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy.

Authors:  M Böhm; M Castellano; M Flesch; C Maack; M Moll; M Paul; F Schiffer; O Zolk
Journal:  Hypertension       Date:  1998-11       Impact factor: 10.190

Review 3.  Nucleus locus ceruleus: new evidence of anatomical and physiological specificity.

Authors:  S L Foote; F E Bloom; G Aston-Jones
Journal:  Physiol Rev       Date:  1983-07       Impact factor: 37.312

4.  Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence.

Authors:  Jerzy Samochowiec; Jolanta Kucharska-Mazur; Ryszard Kaminski; Michael Smolka; Hans Rommelschpacher; Catrin Wernicke; Agnieszka Tymicz; Lutz Gerhardt Schmidt
Journal:  Psychiatry Res       Date:  2002-08-30       Impact factor: 3.222

5.  Orthostatic intolerance is not necessarily related to a specific mutation (Ala457Pro) in the human norepinephrine transporter gene.

Authors:  Sabine Ivancsits; Arthur Heider; Hugo W Rüdiger; Robert Winker
Journal:  Am J Med Sci       Date:  2003-02       Impact factor: 2.378

6.  Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine.

Authors:  G Tanda; F E Pontieri; R Frau; G Di Chiara
Journal:  Eur J Neurosci       Date:  1997-10       Impact factor: 3.386

7.  Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter.

Authors:  M Brüss; J Kunz; B Lingen; H Bönisch
Journal:  Hum Genet       Date:  1993-04       Impact factor: 4.132

8.  The human noradrenaline transporter gene contains multiple polyadenylation sites and two alternatively spliced C-terminal exons.

Authors:  P Pörzgen; H Bönisch; R Hammermann; M Brüss
Journal:  Biochim Biophys Acta       Date:  1998-07-09

9.  Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study.

Authors:  M C Ritz; E J Cone; M J Kuhar
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

10.  Molecular cloning and organization of the coding region of the human norepinephrine transporter gene.

Authors:  P Pörzgen; H Bönisch; M Brüss
Journal:  Biochem Biophys Res Commun       Date:  1995-10-24       Impact factor: 3.575

View more
  2 in total

1.  Detailed analysis of variants in FTO in association with body composition in a cohort of 70-year-olds suggests a weakened effect among elderly.

Authors:  Josefin A Jacobsson; Markus Sällman Almén; Christian Benedict; Lilia A Hedberg; Karl Michaëlsson; Samantha Brooks; Joel Kullberg; Tomas Axelsson; Lars Johansson; Håkan Ahlström; Robert Fredriksson; Lars Lind; Helgi B Schiöth
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

2.  Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study.

Authors:  Ajeet Bhagat Singh; Chad A Bousman; Chee Hong Ng; Keith Byron; Michael Berk
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.